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Objective: to psychometrically test the Brazilian version of the Treatment Satisfaction Questionnaire 
for Medication – TSQM (version 1.4), regarding ceiling and floor effect, practicability, acceptability, 
reliability and validity. Methods: participants with coronary heart disease (n=190) were recruited 
from an outpatient cardiology clinic at a university hospital in Southeastern Brazil and interviewed 
to evaluate their satisfaction with medication using the TSQM (version 1.4) and adherence using 
the Morisky Self-Reported Measure of Medication Adherence Scale and proportion of adherence. 
The Ceiling and Floor effect were analyzed considering the 15% worst and best possible TSQM 
scores; Practicability was assessed by time spent during TSQM interviews; Acceptability by 
proportion of unanswered items and participants who answered all items; Reliability through the 
Cronbach’s alpha coefficient and Validity through the convergent construct validity between the 
TSQM and the adherence measures. Results: TSQM was easily applied. Ceiling effect was found 
in the side effects domain and floor effect in the side effects and global satisfaction domains. 
Evidence of reliability was close to satisfied in all domains. The convergent construct validity 
was partially supported. Conclusions: the Brazilian TSQM presents evidence of acceptability and 
practicability, although its validity was weakly supported and adequate internal consistency was 
observed for one domain.
Descriptors: Nursing; Patient Satisfaction; Medication Adherence; Coronary Disease; 
Psychometrics.
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Introduction
Satisfaction is a patient reported outcome that 
considers the patients’ evaluation of aspects of the 
medical treatment and health care systems(1). The 
interest in these types of measures has increased 
over the past decades, since patients have come to 
be considered as “consumers” and not just as passive 
receivers of health services(2). 
While patient satisfaction with treatment includes 
the assessment of doctor-patient interaction, as well as 
other concomitant therapies, patient satisfaction with 
drug therapy is related only to medications(2). 
The satisfaction with medication can be defined 
as the patient’s evaluation on the process of taking 
the medications and the associated results of its use(2). 
Patients’ satisfaction with their medication has been 
demonstrated to predict the continuation on drug 
treatment, as well as adherence to correct and consistent 
use of drug therapy over time(3). 
Prior studies in cardiology showed that patients 
who were more than 80% adherent to the protocol 
prescription had better clinical outcomes than those who 
were nonadherent(4). Among the factors that possibly 
influence the medication adherence construct, the 
patient satisfaction with drug therapy stands out(2).
Adherence to long-term drug therapy has proven 
to be essential for prevention and control of Coronary 
Heart Disease (CHD). Studies suggest that adherence 
to drug treatment over time results in the reduction 
of new ischemic events(5) and optimization of survival 
and health-related quality of life of patients with CHD(6). 
Moreover, the international literature indicates poor 
adherence to the pharmacological treatment among 
these patients(4). 
Considering the clinical relevance of knowing patients’ 
satisfaction with treatment, researchers have developed 
a wide-ranging questionnaire, aimed at measuring 
satisfaction with medication. The Treatment Satisfaction 
Questionnaire for Medication version 1.4 (TSQM) is a 
generic and broad-based outcome of patient satisfaction 
with medication, which has been validated among 
individuals with different chronic disease conditions(3).  
 The validity and reliability of the TSQM have 
been demonstrated in English, Spanish, Arabic and 
French, providing a robust tool to assess patients’ 
satisfaction with the drug treatment to treat a variety 
of disease conditions(3,7-9). Until this moment, the TSQM 
(version 1.4) had not been tested or validated for 
patients with CHD. 
No other psychometrically validated treatment 
satisfaction with medication measures are available for 
use with patients with Brazilian Portuguese as their native 
language. In addition, it has been demonstrated that 
patient satisfaction with medication predicts medication 
adherence(3), so that satisfied patients are expected to 
be more adherent to prescribed therapeutic regimens(2). 
It is also important to highlight that, if nurses evaluate 
patient satisfaction, it will be possible to prevent 
dissatisfaction and, consequently, non-adherence, 
making possible disease control and improvements in 
their quality of life(6).
Given the importance of providing a reliable and 
valid tool for measuring patient satisfaction in relation 
to drug therapy for the Brazilian scientific community, 
the aim of this study was to psychometrically test the 
Brazilian version of the TSQM (version 1.4) when applied 
to participants with CHD, specifically verifying the 
practicability, acceptability, reliability, ceiling and floor 
effects and construct validity of the Brazilian version of 
the TSQM (version 1.4).
Methods
Study design and participants
A methodological study design was used to reach 
the research goals. The study was conducted at an 
outpatient clinic specialized in cardiology, at a teaching 
hospital in a large urban center in Southeastern Brazil. 
Participants were recruited by convenience, on the 
day of their regular consultation with the cardiologist, 
when they were invited to participate in the research. 
Their agreement was formalized by signing the consent 
form (consent rate was 100%). The sample comprised 
participants with CHD aged over 18 years, with unstable 
angina and/or myocardial infarction. Additional inclusion 
criteria were: to be able to effectively communicate 
verbally and be a current user of at least two life-saving 
drugs for treatment of CHD for a full month prior to 
study enrollment. 
Sample size
The sample size was determined based on 
preliminary data, considering the following: Pearson 
correlation coefficient r=0.60 expected between 
measures of self-reported adherence and satisfaction 
with drug use, precision of 0.3 and a significance 
level of 5% (α=0.05)(10). A sample size of at least 86 
participants was determined. Data from 190 participants 
were gathered during the data collection period.
Data collection
One researcher collected the data between June 
2010 and May 2011 through structured interviews and 
consultation of the medical chart.
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Sociodemographic and clinical data were gathered 
using a validated questionnaire(11). Subsequently, a 
structured interview was conducted in order to measure 
satisfaction with the drug therapy by the application 
of the TSQM (version 1.4). Medication adherence was 
measured by the Morisky Self-Reported Measure of 
Medication Adherence and by quantifying the proportion 
of adherence.
Data analysis
Data were analyzed using the SPSS Statistics - 
version 20 (IBM software), for the following analyses:
Ceiling and Floor effects: The participants’ 15% 
worst results of the scale were considered the floor 
effect and, for the 15% best possible results, the ceiling 
effect(12) was evaluated. 
 Practicability: Assessed by the time spent during 
TSQM interviews.
Acceptability: Assessed by the proportion of 
unanswered items and participants who answered all 
items.
Reliability: The internal consistency was evaluated 
through Cronbach’s alpha, and consistency for Cronbach’s 
alpha was considered to be higher than 0.70(13). 
Validity: The Pearson correlation coefficient was 
applied to test the convergent construct validity between 
the scores of the Brazilian TSQM and the score on the 
Brazilian Morisky Self-Reported Measure of Medication 
Adherence and the proportion of drug adherence. 
Significant correlations close to 0.30 were considered 
satisfactory, despite a small practical value; coefficients 
from 0.30 up to 0.50 were considered moderate and 
coefficients superior to 0.50 were considered strong(14). 
A significance level of 0.05 (p-value) was adopted.
Questionnaires 
Treatment Satisfaction Questionnaire for Medication 
– TSQM (version 1.4)
The TSQM (version 1.4) is a questionnaire that 
measures the satisfaction with the drug therapy, 
considering the last two or three weeks or since the last 
time the patient took the medication.  It is suggested that 
TSQM should be applied as a self-reported measure(3) 
but, in this study, the TSQM was applied as part of an 
interview for the participants to easily comprehend the 
questions. There are 14 questions, distributed over 
4 domains: effectiveness, side effects, convenience 
and global satisfaction. Responses were measured 
through a Likert-type scale of 5 or 7 points, and one 
dichotomous response (question 4). The TSQM (version 
1.4) domain scores were calculated as recommended 
by the instrument’s authors, which is described in detail 
elsewhere(15-16). The score ranges from 0 to 100 in each 
domain and, the higher the score, the greater the patient 
satisfaction with medication(3). 
Treatment satisfaction was assessed using the 
Brazilian version of the TSQM (version 1.4), and the 
copyright was obtained from Quintiles Strategic Research 
Services. The version 1.4 was translated into Brazilian 
Portuguese by qualified translators of the Center on 
Outcomes Research and Education of the United States 
(CORE)(17). The method requires two forward translations 
into the Portuguese language by native speakers. 
Reconciled versions of the two forward translations were 
done by a third independent translator who was a native 
Portuguese speaker, a back-translation of the reconciled 
version by a native English speaker fluent in Portuguese 
and three reviews by native speaking linguists or 
health-related researchers. After the translation, the 
TSQM Brazilian version was linguistically validated in a 
Brazilian sample. These data is not published, however, 
it is available on a certificate offered by Quintiles. 
Morisky Self-Reported Measure of Medication 
Adherence Scale
Consists of a short questionnaire aimed at assessing 
factors related to adherence, developed by Morisky 
and collaborators(18). It consists of four questions with 
the answers measured in a Likert-type scale ranging 
from 1 to 4(19). The sum of responses of the four items 
generates a score that ranges from four to eighteen, 
considering that the lower the score, the more favorable 
for adherence to drug use.
Proportion of medication adherence
This instrument identifies and quantifies the 
drugs in current use, in order to provide the proportion 
(%) of drug adherence. It comprises four variables: 
1) Description of the name and dosage of all drugs 
prescribed; 2) Description of the form of use of each 
drug according to the prescribed dose during the last 
24 hours, 3) during the last week and 4) during the last 
month(19).
Adherence was calculated based on missed doses 
over the last month, reported by the patient using 
the following calculation: [(prescribed doses - missed 
doses) / prescribed dose] x 100%(20). Participants were 
considered adherent if a percentage of consumption of 
prescribed drugs higher or equal to 80% was obtained(4). 
For individuals who used more than one drug, the 
proportion of the use was calculated for each drug 
and then the average percentage of adherence of all 
medications was calculated.
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Ethical considerations
 The investigation conforms to the principles 
outlined in the Declaration of Helsinki and complies with 
resolution 196/96. The Faculty of Medical Science Ethics 
Committee from University of Campinas approved this 
study (Protocol: 2010/07332-0).
Results
Sociodemographic and clinical data
The study sample consisted of 190 participants. 
The sample was composed mainly of men (63.2%) with 
a mean age of 60.2 (SD 10) years, whites 135 (71.1%), 
with companion 135 (71.1%), professionally active 59 
(31%), with 5.4 (SD 4) years of study (Table 1).
The majority 112 (58.9%) of the participants was 
diagnosed with Acute Coronary Syndrome with ST-
segment elevation. Most presented dyslipidemia 184 
(96.8%), hypertension 172 (90.5%) and diabetes 85 
(44.7%). A large percentage 125 (65.8%) was composed 
of smokers. For many, chest pain 103 (54.2%), dyspnea 
93 (48.9%) and lipothymia 88 (46.3%) were experienced 
over the last month. The mean number of symptoms 
in the sample was 2.4 (SD 1.5). Most participants 
126 (66.3%) had been submitted to clinical treatment 
and intervention (Myocardial Revascularization and/or 
percutaneous angioplasty) (Table 2).
Table 1 - Sociodemographic characteristics of participants with coronary heart disease (n=190), Campinas, SP, Brazil, 
2010-2011
Sociodemographic Variables n (%) Mean (SD*) Range Median
Gender
Male 120 (63.2)
Education (years) 5.4 (4) 0-20 4
Age (years) 60.2 (10) 28-87 59.5
Marital Status
With companion 135 (71.1)
Race
Caucasoid 135 (71.1)
Professional Status
Active 59 (31)
Inactive 109 (57.3)
Housewife 22 (11.6)
Monthly income (US$)†
Family 921.4 (665.1) 0-3,447.1 734.5
*SD = Standard Deviation; †Dollar exchange rate: 1.77 on 07/12/2011.
Table 2 - Clinical characteristics of participants with coronary heart disease (n=190), Campinas, SP, Brazil, 2010-2011
 Clinical Variables n (%) Mean (SD*) Range Median
Acute Coronary Syndrome (ACS - n=189)
ST-segment elevation 112 (58.9)
Unstable angina 40 (21.1)
Non ST-segment elevation 37 (19.5)
Years since the last ischemic event 8.3 (4.9) 3-27 6
Number of previous MI 1.4 (1.4) 0-10 1
Associated conditions 
Dyslipidemia 184 (96.8)
Hypertension 172 (90.5)
Diabetes Mellitus 85 (44.7)
Number of clinical conditions 4 (1.7) 1-15 4
Smoking (current and past) 125 (65.8)
Symptoms over the last month
Chest pain 103 (54.2)
Dyspnea 93 (48.9)
(continue...)
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 Clinical Variables n (%) Mean (SD*) Range Median
Lipothymia 88 (46.3)
Number of symptoms over the last month 2.4 (1.5) 0-6 2
Treatment of ACS
 Clinical 61 (32.1)
 Clinical and chirurgical 126 (66.3)
*SD: Standard Deviation; †Left Ventricular Ejection Fraction, ‡LVEF≤58.0%.
Table 3 - Descriptive analyses of medication adherence and satisfaction. Campinas, SP, Brazil, 2010-2011 
Variables n % Mean (SD*) Range Median
Satisfaction Measure
TSQM (version 1.4)
Effectiveness 189 67.7 (8) 27.8-88.9 66.7
Side Effects 190 93.5 (16.9) 12.5-100 100
Convenience 190 66.3 (9.5) 33.3-100 66.7
Global satisfaction 190 69.2 (12.6) 14.3-100 71.4
Adherence Measures
Morisky Self-Reported Scale 190 5.8 (2.2) 4-15 5
Adherence proportion
Life-savings drug adherence† 
Beta-blockers 143 94.4 (16) 0-100 100
Adherent 88.8
Antiplatelet 170 92.5 (24.1) 0-100 100
Adherent 90.6
Statins 127 95.5 (16.3) 0-100 100
Adherent 91.8
Life-savings drugs (associated)‡ 190 94.2 (13) 0-100 100
Adherent 87.9
Drugs for symptom relief§
Nitrate 45 88.4 (25.5) 0-100 100
Adherent 84.4
Diuretic 90 96.7 (12.4) 13-100 100
Adherent 93.3
Digitalis 7 36.1 (47.7) 0-100 0
Adherent 28.6
Drugs for symptom relief (associated)§ 190 93.1 (14.1) 0-100 100
Adherent 86.3
*SD: Standard Deviation; †Individuals who presented adherence ≥80% were considered adherent; ‡Drug therapy related to the reduction of morbidity and 
mortality in coronary heart disease - life-saving therapy - converting enzyme inhibitor (ACEI) or angiotensin receptor antagonists (ARBs), beta-blockers, 
antiplatelet agents and statins; §Drugs used for symptoms relief in coronary heart disease: digoxin, diuretics and nitrates.
Table 2 - (continuation)
Practicability, acceptability and ceiling/floor effects
Regarding the acceptability, only 4 items were not 
answered among the participants enrolled (Question 
2 – 1 time not answered; question 11 – 3 times not 
answered; question 12 – 7 times not answered; question 
13 – 2 times not answered). As for the practicability, 
the TSQM demonstrated average application time of 4.6 
(SD 2) minutes. Descriptive data of the measures of the 
TSQM, the Morisky Self-Reported Measure of Medication 
Adherence Scale and the proportion of adherence are 
presented in Table 3. 
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Considering that the scores of the Brazilian TSQM 
ranged from 0 up to 100 in each domain and that, 
the higher the score, the greater the satisfaction with 
the drug therapy. Higher scores were found in the 
side effects 93.5 (SD 16.9) domain and lower scores 
were reported in the convenience 66.3 (SD 9.5), 
effectiveness 67.7 (SD 8) and global satisfaction 69.2 
(SD 2.6) domains (Table 3). Regarding self-reported 
measures of adherence, participants with a proportion 
of adherence larger than 80% were consider adherent; 
for the life-saving medications, the adherence was 
94.2 (SD 13) and, for symptoms-relief medication, 
the score was 93.1 (SD 12.1). Analyses of the Morisky 
Self-Reported Measure of Medication Adherence also 
demonstrated the presence of factors related to the 
adherence in the sample with 5.8 (SD 2.2). 
The analyses of the ceiling and floor effects 
provide evidence that there was ceiling effect in 
the side effects (90.5%), convenience (14.2%), 
effectiveness (15.8%) and global satisfaction (25.8%) 
domains. The floor effect was discreetly observed in 
the side effects (0.5%) and global satisfaction (1.1%) 
domains.
Reliability Analyses
Evidences of internal consistency were observed in 
TSQM (version 1.4), as the Cronbach’s alpha (α) was 
satisfactory for side effects α=0.71 domain and close to 
satisfactory for the effectiveness α=0.69; convenience 
α=0.67 and global satisfaction α=0.69 domains. 
Validity
Contrary to the assumptions previously established, 
significant correlations were small or not found between 
the scores of TSQM (version 1.4) and the scores on the 
Brazilian version of the Morisky Self-Reported Measure of 
Medication Adherence and the proportion of adherence 
(Table 4). 
Table 4 - Pearson’s correlation coefficients between TSQM (version 1.4) and adherence measures. Campinas, SP, 
Brazil, 2010-2011 
*r Adherence
† -
Symptoms relief
Adherence†– 
Life-saving Morisky
TSQM - 
Effectiveness
TSQM – 
Side Effects
TSQM – 
Convenience
TSQM – Global 
Satisfaction
Adherence† – Symptoms 
relief 1.0
Adherence† – Life-saving 0.82‡ 1.0
Morisky -0.24‡ - 0.26‡ 1.0
TSQM - Effectiveness 0.02 0.06 -0.07 1.0
TSQM –
Side Effects 0.16
§ 0.04 -0.18§ 0.11 1.0
TSQM – Convenience -0.03 0.05 -0.09 0.19‡ 0.02 1.0
TSQM – Global 
Satisfaction -0.04 0.03 -0.16
‡ 0.46‡ -0.02 0.15§ 1.0
*r = Pearson’s correlation coefficients; †Proportion of adherence; ‡p<0.01; §p≤0.05.
Discussion
The findings suggest the practicability and 
acceptability of the Brazilian’s TSQM, evidenced by the 
short average time of application (4.6 minutes) with 
99.5% of the items answered. In the original study(3), 
the mean time for application of the instrument was not 
reported.
Although most of the participants responded to all 
items, some difficulty was observed in understanding 
question 4, which belongs to the side effects domain, 
with regard to the meaning of the terms “secondary” 
and “collateral”, used for translating the expression 
“side effects” in Brazilian Portuguese, as well as 
for understanding the terms “convenient” and 
“inconvenient”, listed in question 11, which belong to 
the convenience domain. These items need revision in 
order to optimize the instrument for promoting better 
comprehension in a population with few years of study 
and low socioeconomic level(21).
The results also indicated the presence of a minor 
ceiling effect in the effectiveness (15.8%), convenience 
(14.2%), global satisfaction (25.8%) domains and 
90.5% in the side effects domain. It is also important 
to highlight that 81.1% of the participants reported no 
side effects. The score differences might be due to a 
systematic bias, such as social desirability affecting all 
items (the often unconscious desire to give a positive 
image to others by giving responses that correspond to 
socially admitted opinions)(22). The social desirability bias 
can be changed according to the way the questionnaire 
is applied; it is more frequent in interview methods. 
Floor effect was not found in significant proportions. 
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It is noteworthy that the ceiling effect occurs when 
a percentage of the sample scores the highest possible 
level of the measure, which impedes the detection of 
changes in situations of improvement of the health 
status. The floor effect occurs when a percentage of the 
sample scores the lowest possible level of the measure, 
which impedes the detection of changes in situations of 
worsening of the health status(10).
The detection of these effects may indicate the 
impaired responsiveness of the instrument - the ability 
of the instrument to measure the magnitude of the 
change in a clinical condition over time(23). Therefore, 
the Brazilian TSQM (version 1.4) can be considered 
potentially responsive regarding the measure of 
worsening of the health status, since a small floor 
effect was evidenced. Nevertheless, the current data 
suggest that there may not be a limitation regarding 
the detection of improvement of the health status; the 
ceiling effect was detected in the side effects domain 
(90.5%). This is expected, however, when considering 
the scoring technique of this domain(15-16). Other studies 
reported issues regarding the distribution of the scores 
and ceiling and floor effects are addressed in the TSQM 
(version 1.4), with evidence of ceiling effect in the side 
effects and convenience domains(3,22). 
Possible reasons for the occurrence of inadequate 
distribution of the scores were evaluated by removing 
respondents who infrequently reported occurrence of 
side effects, which resulted in a normal distribution of 
scores, suggesting that respondents were satisfied with 
drug treatment when side effects were infrequent(3). The 
authors highlight that such findings should not be treated 
as a simple response bias, but as a result of a complex 
interaction between the feasibility, alternative treatments 
effectiveness and respondent’s health status over time(3).
In the present study, the reliability analysis was 
satisfactory, or close to it. The internal consistency of 
items, estimated by Cronbach’s alpha coefficient, was 
demonstrated previously in the original study(3), in which 
the Cronbach’s alpha coefficient ranged from 0.86 up to 
0.90. Other studies that applied the TSQM to assess the 
satisfaction with drug treatment had similar results(22,24). 
As opposed to the previously established 
hypotheses, the TSQM presented no significant 
correlations with the measures of adherence to drug 
use (Table 4). The lower the Morisky score, the higher 
the favorability to adherence and, regarding the TSQM, 
the higher the score, the better the patient satisfaction, 
so a negative correlation is expected between these 
questionnaires. Nevertheless, values closer to one 
are still expected, not considering the sign. The lack 
of significant correlations between the measure of 
satisfaction (TSQM) and the adherence measures can 
be explained by the TSQM not including constructs 
such as medical care and treatment impact, relevant 
aspects pertaining to the construct of satisfaction, 
which can predict treatment adherence(9). Other studies 
evaluated the correlation between patient satisfaction 
and medication adherence, and found a correlation(22,25). 
However, none of them correlated TSQM (version 1.4) 
and the 4-item Morisky Self-Reported Measure of 
Medication Adherence. Instead, it was common to use 
the 8-item Morisky scale. It is important to highlight that 
the 8-item Morisky Medication Adherence scale is not 
available in Brazilian Portuguese.    
Adherence consists of a complex measure for 
which there is no gold standard. In the present 
study, adherence was assessed by two instruments 
as recommended elsewhere(26), in order to respect its 
aspects and maximize its accuracy. Even though the 
Morisky Self-Reported Measure of Medication Adherence 
is widely used, its reliability varies among different 
samples(19). Future studies could consider objective 
measures of adherence (such as direct observation of 
medication intake or use of biological markers), and 
the Morisky self-reported measure would increase the 
accuracy of the adherence measure.  
In the future, health care providers in the field 
of chronic diseases have to focus their attention on the 
aging population, their prevalence will be much more 
frequent, as well as the necessity of continuous and 
persistent medication treatment(3). It is known that patient 
satisfaction influences the health behavior and would 
be crucial in this process of treatment in patients with 
chronic diseases, mainly in patients with CHD, in which 
the treatment adherence reduces the number of ischemic 
events and improves quality of life. Nurses as health 
educators would be pivotal in educating patients about the 
self-management of diseases, thus increasing the patient 
satisfaction and achieving high adherence rates(25).
Further studies are recommended in order to 
deeply evaluate the psychometric performance of the 
TSQM, aimed at confirming its validity, sensitivity and 
the structure of the factors. The results of this study 
present relevant implications for nurses and other 
health professionals, since they support a stronger 
evaluation of a questionnaire that can be used to assess 
the effectiveness of interventions to improve patients’ 
satisfaction with their drug treatment.
Limitations
One of the limitations were the interview technique 
in which the instruments were applied, including TSQM 
(version 1.4), although the application of the TSQM as a 
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self-reported measure is recommended, and interviews 
can lead to social desirability. Even without testing 
the cognitive function or levels of comprehension, the 
low levels of study and family income motivated this 
approach, as the majority of the Brazilian population 
was considered. 
As for the construct validity, it is important to 
highlight that there is no gold standard for an adherence 
measurement and, on top of that, adherence can be 
deceptive – in order to achieve more precise results, we 
have applied two questionnaires to measure this construct.
Conclusion
The results of this study indicate that the Brazilian 
TSQM (version 1.4) is a questionnaire with easy 
application, with evidence of acceptability and potential 
sensitivity in detecting worsening regarding patients’ 
satisfaction with their medication, evidenced by the 
low floor effect, as well as the limitation in detecting 
improvement regarding patient satisfaction by the 
finding of a substantial ceiling effect in the side effects 
domain. Construct validity was weakly supported, since 
small significant correlations were observed with the 
general measure of satisfaction and adherence.
In the era of patient safety, nurses play a pivotal 
role as they not only provide direct health care to 
patients, but also regarding their health education and 
behavior. Patients who perceive their medication to be 
ineffective, laden with side effects, or too inconvenient to 
use are less likely to take their medication as prescribed. 
Thus, dissatisfaction with medication may affect the 
effectiveness of treatment and result in treatment 
failure. Nurses may conduct regular evaluation of patient 
satisfaction by applying the TSQM, which aids the health 
team to monitor individuals whose current experiences 
may increase the risk of low medication adherence.
Further studies are recommended in order to 
confirm the structure of the factors (factor analysis) of 
the Brazilian version of the TSQM and its validity, as well 
as to investigate its sensitivity and responsiveness.
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